Compare EVGO & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVGO | ORGO |
|---|---|---|
| Founded | 2010 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.6M | 166.0M |
| IPO Year | 2020 | 2016 |
| Metric | EVGO | ORGO |
|---|---|---|
| Price | $1.04 | $1.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 2 |
| Target Price | ★ $3.34 | $2.00 |
| AVG Volume (30 Days) | ★ 2.8M | 750.4K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.39 | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | $54,588,000.00 | ★ $564,169,000.00 |
| Revenue This Year | $6.04 | N/A |
| Revenue Next Year | $28.83 | $37.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 145.74 | 17.04 |
| 52 Week Low | $1.02 | $0.93 |
| 52 Week High | $4.29 | $7.08 |
| Indicator | EVGO | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 30.74 | 26.71 |
| Support Level | N/A | N/A |
| Resistance Level | $1.53 | $2.57 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 3.95 | 23.06 |
EVgo Inc is an EV fast charging provider. The company deploys charging infrastructure by partnering with retailers, grocery stores, restaurants, gas stations, rideshare operators, and autonomous vehicle companies across the U.S., and serves the EV commercial segment by deploying fleet-charging solutions for light-duty EV fleets at depot locations, off-site charging hubs, or through its public network. It also owns PlugShare, a platform for EV drivers to locate public charging stations, plan trips and share charging experiences, which also provides charging location data licensing, infrastructure analysis, and EV driver research. It also derives revenue from the sale of regulatory credits earned from participation in LCFS programs and other carbon or emissions trading schemes in the U.S.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.